# Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

> **NCT05183828** · PHASE4 · RECRUITING · sponsor: **University of Washington** · enrollment: 68 (estimated)

## Conditions studied

- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- Breast Adenocarcinoma
- Invasive Breast Carcinoma of No Special Type

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Letrozole
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT05183828
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-23
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2026-01-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05183828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05183828, "Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05183828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*